Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 6 Lymphocyte subpopulations in alemtuzumab (Alem)-treated patients and controls (CON)

From: Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies

Cell count, median and range (×109/L) Percentage of lymphocyte population Previous cell count, median and range (×109/L)
Lymphocyte subpopulation ALEM (n = 9*) CON (n = 8) P valuea ALEM (n = 9*) CON (n = 8) ALEM cohort 2012 data (n = 20) ALEM cohort 2001 data (n = 40)
Total lymphocytes 0.93 (0.41 − 3.1) 1.125 (0.34 − 2.38) 0.7001 n/a n/a 1.15 (0.3 − 2.9) n/a
CD4+ T cells 0.37 (0.13 − 0.94) 0.48 (0.13 − 0.65) 0.4406 30.5 (11.5 − 46.7) 34.9 (13.3 − 43.7) 0.55 (0.12 − 1.94) 0.000185
CD4+ naïve T cells 0.23 (0.01 − 0.61) 0.21 (0.07 − 0.29) 1 20.3 (1.23 − 30.5) 13.3 (4.15 − 20.6) 0.09 (0.01 − 0.65) n/a
CD4+ total memory T cells 0.13 (0.11–0.34) 0.26 (0.06 − 0.56) 0.2359 12.52 (7.26 − 18.93) 18.5 (9.3 − 29.74) 0.37 (0.10 − 0.73) n/a
CD4+ central memory T cells 0.08 (0.05 − 0.16) 0.2 (0.03 − 0.42) 0.0360 7.24 (4.74 − 13.28) 12.82 (6.73 − 22.45) 0.11 (0.02 − 0.07) n/a
CD4+ effector memory T cells 0.05 (0.02–0.17) 0.06 (0.02 − 0.14) 0.9626 4.37 (1.81 − 7.58) 3.78 (2.42 − 7.56) 0.26 (0.07 − 0.55) n/a
CD8+ T cells 0.10 (0.04 − 0.72) 0.11 (0.05 − 0.42) 0.9626 7.27 (4.95 − 31.9) 9.04 (3.96 − 22.7) 0.25 (0.02 − 0.78) 0.00009
CD8+ naïve T cells 0.05 (0.01 − 0.14) 0.02 (0.01 − 0.08) 0.2766 3.32 (0.46 − 7.27) 1.57 (0.64 − 5.94) 0.05 (0.001 − 0.17) n/a
CD8+ total memory T cells 0.02 (0.07 − 0.13) 0.06 (0.01 − 0.19) 0.0592 1.82 (0.72 − 4.41) 3.97 (0.62 − 0.55) 0.12 (0.01 − 0.41) n/a
CD8+ central memory T cells 0.01 (0.003 − 0.01) 0.02 (0.005 − 0.11) 0.0274 0.69 (0.26 − 1.33) 1.84 (0.34 − 6.01) 0.02 (0.003 − 0.12) n/a
CD8+ effector memory T cells 0.01 (0.007–0.07) 0.03 (0.007 − 0.1) 0.1672 1.51 (0.45 − 3.2) 1.94 (0.31 − 5.72) 0.07 (0.01 − 0.37) n/a
B cells 0.01 (0.01 − 0.05) 0.09 (0.02 − 0.2) 0.0041 1.7 (1.12 − 4.15) 8.96 (4.64 − 17.5) 0.08 (0.02 − 0.26) 0.000115
Naïve B cells 0.01 (0.001–0.02) 0.08 (0.7 − 0.14) 0.0041 1.18 (0.71 − 2.69) 5.47 (3.62 − 16.4) 0.06 (0.01 − 0.23) n/a
Memory B cells 0.006 (0.002 − 0.02) 0.01 (0.008–0.03) 0.1282 0.56 (0.37 − 0.86) 1.19 (0.22 − 3.91) 0.02 (0.002 − 0.19) n/a
CD5+ B cells 0.001 (0.001 − 0.005) 0.03 (0.001 − 0.08) 0.0175 0.28 (0.084 − 0.94) 2.22 (0.33 − 3.48) 0.005 (0.0009 − 0.03) n/a
CD19+CD24hiCD38hi
B cells
0.001 (0.00005 − 0.002) 0.009 (0.0008 − 0.038) 0.003 0.061 (0.014 − 0.42) 0.70 (0.51 − 2.31) n/a n/a
NK cells 0.1 (0.02 − 0.17) 0.07 (0.02 − 0.10) 0.4234 10.5 (3.3 − 19.2) 8.35 (4.84 − 13.3) 0.06 (0.01 − 0.2) n/a
NK T cells 0.01 (0.0006–0.13) 0.009 (0.002 − 0.02) 0.6730 0.76 (0.12 − 4.34) 0.73 (0.52 − 1.27) 0.05 (0.003–0.27) n/a
  1. Median values and ranges are displayed for both absolute number and percentage of lymphocyte population. a P value for alemtuzumab versus established rheumatoid arthritis cell count absolute number); values in italics are significant. Gating strategies were as follows: CD4+ T cells: CD3+CD4+; CD4+ naïve T cells: CD3+CD4+CD45RA+CD62L+; CD4+ total memory T cells: CD3+CD4+CD45RA-; CD4+ central memory T cells: CD3+CD4+CD45RA-CD62L+; CD4+ effector memory T cells: CD3+CD4+CD45RA-CD62L-; CD8+ T cells: CD3+CD4-, CD8+ naïve T cells: CD3+CD4-CD45RA+CD62L+; CD8+ total memory T cells: CD3+CD4-CD45RA-; CD8+ central memory T cells: CD3+CD4-CD45RA-CD62L+; CD4+ effector memory T cells: CD3+CD4-CD45RA-CD62L-; B cells: CD19+; Naïve B cells: CD19+CD27-; Memory B cells: CD19+CD27+; CD5+ B cells: CD19+CD5+; CD19+CD24hiCD38hi B cells: CD19+CD24hiCD38hi; NK Cells: CD3-CD56+, NK T Cells: CD3+CD56+. For comparison previous analyses (years 2001 and 2012) of lymphocyte subpopulations of the alemtuzumab cohort are included. *Single patient had rituximab within the preceding month and was excluded from B-cell analyses. NK natural killer. n/a not available